Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Pancrelipase→

Pancrelipase Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
53608-75-6
FDA UNII
FQ3DRG0N5K
PubChem Substance Record
SID 481101777
Drug class
Pancreatic enzyme replacement therapydigestive enzyme preparation
Mechanism of action
Supplies exogenous lipase, protease and amylase to replace pancreatic enzymes that are deficient in exocrine pancreatic insufficiency, supporting digestion of dietary fats, proteins and carbohydrates.
Indications / reported uses
  • Treatment of exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, pancreatectomy or other conditions associated with pancreatic enzyme deficiency.

Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020725s003lbl.pdf · https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=pancrelipase

Identification source: PubChem substance record (SID 481101777; no discrete CID). Pancrelipase is a preparation of pancreatic enzymes. The mixture has no single molecular formula or molecular weight; PubChem identifies the substance record and the preparation CAS/UNII.

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Pancrelipase Environmental Risk Assessment (ERA) (the Pancrelipase ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.